2y5k
From Proteopedia
(Difference between revisions)
(6 intermediate revisions not shown.) | |||
Line 1: | Line 1: | ||
- | {{STRUCTURE_2y5k| PDB=2y5k | SCENE= }} | ||
- | ===ORALLY ACTIVE AMINOPYRIDINES AS INHIBITORS OF TETRAMERIC FRUCTOSE 1,6-BISPHOSPHATASE=== | ||
- | {{ABSTRACT_PUBMED_21550236}} | ||
- | == | + | ==Orally active aminopyridines as inhibitors of tetrameric fructose 1,6- bisphosphatase== |
- | [[http://www.uniprot.org/uniprot/F16P1_HUMAN F16P1_HUMAN | + | <StructureSection load='2y5k' size='340' side='right'caption='[[2y5k]], [[Resolution|resolution]] 2.10Å' scene=''> |
+ | == Structural highlights == | ||
+ | <table><tr><td colspan='2'>[[2y5k]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2Y5K OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2Y5K FirstGlance]. <br> | ||
+ | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.1Å</td></tr> | ||
+ | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=YCU:1-[5-(2-METHOXYETHYL)-4-METHYL-THIOPHEN-2-YL]SULFONYL-3-[4-METHOXY-6-(METHYLCARBAMOYLAMINO)PYRIDIN-2-YL]UREA'>YCU</scene></td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2y5k FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2y5k OCA], [https://pdbe.org/2y5k PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2y5k RCSB], [https://www.ebi.ac.uk/pdbsum/2y5k PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2y5k ProSAT]</span></td></tr> | ||
+ | </table> | ||
+ | == Disease == | ||
+ | [https://www.uniprot.org/uniprot/F16P1_HUMAN F16P1_HUMAN] Defects in FBP1 are the cause of fructose-1,6-bisphosphatase deficiency (FBPD) [MIM:[https://omim.org/entry/229700 229700]. FBPD is inherited as an autosomal recessive disorder mainly in the liver and causes life-threatening episodes of hypoglycemia and metabolic acidosis (lactacidemia) in newborn infants or young children.<ref>PMID:9382095</ref> <ref>PMID:12126934</ref> | ||
+ | == Function == | ||
+ | [https://www.uniprot.org/uniprot/F16P1_HUMAN F16P1_HUMAN] | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | A novel sulfonylureido pyridine series exemplified by compound 19 yielded potent inhibitors of FBPase showing significant glucose reduction and modest glycogen lowering in the acute db/db mouse model for Type-2 diabetes. Our inhibitors occupy the allosteric binding site and also extend into the dyad interface region of tetrameric FBPase. | ||
- | + | Orally active aminopyridines as inhibitors of tetrameric fructose-1,6-bisphosphatase.,Hebeisen P, Haap W, Kuhn B, Mohr P, Wessel HP, Zutter U, Kirchner S, Ruf A, Benz J, Joseph C, Alvarez-Sanchez R, Gubler M, Schott B, Benardeau A, Tozzo E, Kitas E Bioorg Med Chem Lett. 2011 Jun 1;21(11):3237-42. Epub 2011 Apr 20. PMID:21550236<ref>PMID:21550236</ref> | |
- | + | ||
- | == | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> |
- | + | </div> | |
+ | <div class="pdbe-citations 2y5k" style="background-color:#fffaf0;"></div> | ||
- | == | + | ==See Also== |
- | + | *[[Fructose-1%2C6-bisphosphatase 3D structures|Fructose-1%2C6-bisphosphatase 3D structures]] | |
- | + | == References == | |
+ | <references/> | ||
+ | __TOC__ | ||
+ | </StructureSection> | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
- | [[Category: Alvarez-Sanchez | + | [[Category: Large Structures]] |
- | [[Category: Benardeau | + | [[Category: Alvarez-Sanchez R]] |
- | [[Category: Benz | + | [[Category: Benardeau A]] |
- | [[Category: Gubler | + | [[Category: Benz J]] |
- | [[Category: Haap | + | [[Category: Gubler M]] |
- | [[Category: Hebeisen | + | [[Category: Haap W]] |
- | [[Category: Joseph | + | [[Category: Hebeisen P]] |
- | [[Category: Kirchner | + | [[Category: Joseph C]] |
- | [[Category: Kitas | + | [[Category: Kirchner S]] |
- | [[Category: Kuhn | + | [[Category: Kitas E]] |
- | [[Category: Mohr | + | [[Category: Kuhn B]] |
- | [[Category: Ruf | + | [[Category: Mohr P]] |
- | [[Category: Schott | + | [[Category: Ruf A]] |
- | [[Category: Tozzo | + | [[Category: Schott B]] |
- | [[Category: Wessel | + | [[Category: Tozzo E]] |
- | [[Category: Zutter | + | [[Category: Wessel HP]] |
- | + | [[Category: Zutter U]] |
Current revision
Orally active aminopyridines as inhibitors of tetrameric fructose 1,6- bisphosphatase
|
Categories: Homo sapiens | Large Structures | Alvarez-Sanchez R | Benardeau A | Benz J | Gubler M | Haap W | Hebeisen P | Joseph C | Kirchner S | Kitas E | Kuhn B | Mohr P | Ruf A | Schott B | Tozzo E | Wessel HP | Zutter U